RAIN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 jan 2024 @ 22:00):

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States...

Stats
Dagens volum	3.70M
Gjennomsnittsvolum	238 293
Markedsverdi	44.01M
EPS	$0 ( 2024-03-14 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.585
ATR14	$0.0380 (3.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-26	Tang Kevin C	Sell	3 850 513	Common Stock
2024-01-25	Bvf Partners L P/il	Sell	185 388	Common Stock, $0.001 par value
2024-01-25	Bvf Partners L P/il	Sell	341 547	Non-Voting Common Stock, $0.001 par value
2024-01-26	Bvf Partners L P/il	Sell	35 000	Stock Option (Right to Buy)
2024-01-26	Bvf Partners L P/il	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-57.46
Last 98 transactions
Buy: 6 387 020 \| Sell: 11 238 556

Volum Korrelasjon

Lang: 0.27 (neutral)

Kort: -0.45 (neutral)

Signal:(53.89) Neutral

Rain Therapeutics Inc. Korrelasjon

10 Mest positive korrelasjoner
KVSC	0.96
PPD	0.957
QQD	0.949
QQC	0.947
FTIV	0.944
ESTA	0.943
DXJS	0.941
GEEX	0.94
ADTH	0.938
EGLE	0.937

10 Mest negative korrelasjoner
OM	-0.969
TSLA	-0.964
WW	-0.96
NVTS	-0.956
GEVO	-0.956
OPI	-0.955
FWRD	-0.954
CLNE	-0.953
VUZI	-0.952
AEHR	-0.945

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Rain Therapeutics Inc. Korrelasjon - Valuta/Råvare

0.59
( weak )

0.82
( strong )

0.00
( neutral )

0.44
( neutral )

-0.50
( neutral )

-0.62
( weak negative )

Rain Therapeutics Inc. Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.71

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.71

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.942

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.980

Financial Reports:

No articles found.

Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Sanntidsoppdatering for Rain Therapeutics Inc. [RAIN]

Upcoming Earnings Alert